Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.molimm.2009.01.019
DC FieldValue
dc.titleGenome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition
dc.contributor.authorJia, J.
dc.contributor.authorCui, J.
dc.contributor.authorLiu, X.
dc.contributor.authorHan, J.
dc.contributor.authorYang, S.
dc.contributor.authorWei, Y.
dc.contributor.authorChen, Y.
dc.date.accessioned2014-10-27T08:29:21Z
dc.date.available2014-10-27T08:29:21Z
dc.date.issued2009-05
dc.identifier.citationJia, J., Cui, J., Liu, X., Han, J., Yang, S., Wei, Y., Chen, Y. (2009-05). Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition. Molecular Immunology 46 (8-9) : 1824-1829. ScholarBank@NUS Repository. https://doi.org/10.1016/j.molimm.2009.01.019
dc.identifier.issn01615890
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/100755
dc.description.abstractBackground: Tumor-specific antigens (TSAs) are potential sources of cancer vaccines, some of which are derived from T-cell epitopes of over-expressed mutant proteins to elicit immunogenicity and overcome tolerance and evasion. The lack of effective vaccines for many cancers has prompted strong interest in improved TSA search methods. Recent progresses in profiling somatic mutations and expressions of human cancer genomes, and in predicting T-cell epitopes enable genome-scale TSA search by collectively analyzing these profiles. Such a collective approach has not been explored in spite of the availability and usage of individual methods. Methodology: Genome-scale TSA search was conducted by genome-scale search of tumor-specific mutations in differentially over-expressed genes of specific cancers based on tumor-specific somatic mutation and microarray gene expression data, followed by T-cell recognition analysis of the identified mutant and over-expressed peptides to determine if they are substrates of proteasomal cleavage, TAP mediated transport and MHC-I alleles capable of eliciting immune response. The performance of our method was tested against 12 and 4 known T-cell defined melanoma and lung cancer TSAs in the Cancer Immunity database. Conclusions: Our approach identified 50% and 75% of the 12 and 4 known TSAs and predicted from the human cancer genomes additional 8-250 and 14-359 putative TSAs of 5 and 3 HLA alleles respectively. The known TSA hit rates (1.9% and 0.8%) are enriched by 29-fold and 35-fold over those of mutation analysis. The numbers of predicted TSAs are within the testing range of typical screening campaigns. Noises in expression data of small sample sizes appear to be a major factor for misidentification of known TSAs. With improved data quality and analysis methods, the collective approach is potentially useful for facilitating genome-scale TSA search. © 2009 Elsevier Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.molimm.2009.01.019
dc.sourceScopus
dc.subjectCancer vaccines
dc.subjectHuman cancer genomes
dc.subjectTumor-specific antigens
dc.typeArticle
dc.contributor.departmentBIOLOGICAL SCIENCES
dc.description.doi10.1016/j.molimm.2009.01.019
dc.description.sourcetitleMolecular Immunology
dc.description.volume46
dc.description.issue8-9
dc.description.page1824-1829
dc.description.codenIMCHA
dc.identifier.isiut000266190000030
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

5
checked on May 13, 2022

WEB OF SCIENCETM
Citations

5
checked on May 13, 2022

Page view(s)

142
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.